A recent research work by the University of Granada advises post-menopausal women the use of Replacement Hormone Therapy (RHT) for at least five years.
The study reveals that the fears associated with the RHT are product of disinformation and are often against clinical evidences. Some of those concerns are fear of collateral effects such as weight gain, breast cancer or the risk of a thromboembolic disease.
The passing of time makes ovaries lose their ability to produce estrogens and progesterone, the hormones which regulate the menstrual cycle. In this stage, when menstruation cesses, there appear physical and psychical changes such as hot flushes, sweating, vaginal dryness, articulation and bone pain, headaches, insomnia, sadness, depression and loss of memory, known as climateric symptoms. In Spain, the average age for the cessation of the menstrual cycle is 50 years old. In the Western countries, about 17% of the population belongs to the post-menstrual group.
Against the discomfort derived from the cessation of menstruation, there are medical treatments which contribute to maintain the quality of life of women in the face of the described changes. One of the treatments proposed is the so-called Replacement Hormone Therapy (RHT).
Fears about this therapy have been erroneously exaggerated, attributing to it secondary effects such as weight gain, breast cancer and risk of a thromboembolic disease.
A study carried out at the University of Granada on more than 500 postmenopausal patients rationalizes the fears above mentioned; and it concludes recommending the use of the hormone therapy, if necessary, for at least five years, under periodic medical controls.
The research work has been read as a doctoral thesis by Dr Otilia Ruth González Vanegas, under the supervision of Dr José Luis Cuadros López and Dr Rosa María Sabatel López (Department of Medicine of the UGR, San Cecilio University Hospital) and Dr Ángela María Cuadros Celorrio (Hospital of Úbeda).